Talk:Tinospora cordifolia
This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||
|
Common names in other languages
This material is unencyclopedic per
Sanskrit: guduchi, amrta, cinnodbhava (छिन्नोद्भवा) ,etc Punjabi: گلو (Gllow), Telugu: తిప్ప తీగ (Tippa-teega), Tamil: சீந்தில் கொடி (Shindilakodi),siva Malayalam: ചിറ്റമൃത് (Amruthu, Chittamruthu), Kannada: ಅಮೃತ ಬಳ್ಳಿ (Amrutha balli),[14] Khmer: បណ្តូលពេជ្រ (bândaul pich), Sinhala: රසකිද Rasakinda, Thai: บอระเพ็ด (boraphét), Lao: ເຄືອເຂົາຫໍPali: galocī, Hindi:geloy (गिलोय), guruc (गुरुच), gurcha, Gujarati: galac, garo, gadu vell, Bengali: Guloncho (গুলঞ্চ), Marathi: Guduchi (गुडूची), Gulvel (गुळवेल), Odia: ଗୁଳୁଚୀ Guluchi, Myanmar: ဆင်တုံးမနွယ် Nepali: Gurjo (गुर्जो). Konkani: amritvel Manipuri name – ningthou khongli Mizo: theisawntlung Urdu: gurch, guluncha Sanskrit Synonyms: There are different Sanskrit Synonyms for Tinospora, mainly denoting its properties or characteristics. For example: Amrita (अमृता) - it is one of the most used synonym. It means nectar. Many formulations use this name of Guduchi. Example: Amritottara Kashaya, Amritarishta, Guduchi (गुडूची)– It protects and guards body from diseases. Chakrangi, (चक्रांगी) Chakralakshana (चक्रलक्षणा)– wheel-like appearance in transverse section of stem. Chandrahasa (चंद्रहासा)– It refers to the moon like appearance of transversely cut stem. Chinnaruha(छिन्नरुहा), Chinnodbhava (छिन्नोद्भवा) – Regular growth of plant even if it is cut-off several times. Regular emergence of plant even if it is cut-off several times. Jwarari(ज्वरारि), Jwaranashini ज्वरनाशिनी)– Useful against fever Ayattha, Amravalli, Kundali, Guduchika, Jivantika, Tantrika, Devanirmita, Dhara, Nagakanyaka, Bhishakpriya, Madhuparni, Somavalli, Vayastha, etc
Use in Ayurveda
- ping WP:MEDASSESS says about such initial research -]
The results might – in some cases – be appropriate for inclusion in an article specifically dedicated to the treatment in question or to the researchers or businesses involved in it. Such information, particularly when citing secondary sources, may be appropriate in research sections of disease articles. To prevent misunderstanding, the text should clearly identify the level of research cited (e.g., "first-in-human safety testing").
Hemantha (talk) 05:07, 15 May 2022 (UTC)
References
- ^ Guduchi, Ashwagandha, Ayush-64: Centre releases Ayurveda protocol to combat Covid-19, The New Indian Express, 6 October 2020
- ^ Is giloy a ‘magic Covid herb’ or liver killer? Mumbai study casts shadow on ayurvedic remedy, The Print, July 2021
- ^ Giloy safe but be cautious of similar looking plants in circulation, The Hindu, 8 October 2021
- ^ As COVID Surged, India Had a Silent Outbreak of Giloy-Induced Liver Injury, Banjot Kaur, 17 Feb 2022, The Wire
According to the Drugs.com review, - and as shown in your news sources - there are only case reports to discuss the potential for liver injury, and overall, there is little reliable information about dosing for any given illness or its clinical effects. Due to their perpetuation of quackery, Ayurveda and AYUSH sources are unreliable and unusable. I made this edit to clarify. Zefr (talk) 05:32, 15 May 2022 (UTC)
- WP:RS, used only to support the fact that the ministry had been promoting it; not to make any medical or quack-ish claim.
- Further, can you please tell me which text in the drugs.com reference supports your new addition that there is no evidence that it is effective or safe? The ref actually seems to say something quite opposite -
At Ayurvedic therapeutic doses, no toxicity has been observed
. I see that even the previously existing text (about regulatory approvals) is unsupported by that ref, but your version seems to be even more so. Hemantha (talk) 13:03, 15 May 2022 (UTC)- Under Uses and pharmacology in the Drugs.com article, all the studies reviewed and discussion are about "no clinical data" concerning efficacy and safety. Concerning your sources - which are brief news reports, WP:MEDASSESS to determine evidence quality: a) Ayurveda and AYUSH sources are not reliable, and these were used to produce the news; b) the news stories are about liver toxicity case reports, which have not been reported by the India Ministry of Health, but rather via AYUSH, a source that treats Ayurveda as a valid profession, not the quackery that it is. Summarizing, MEDASSESS (left pyramid) would say that there is not enough evidence and no review to verify the significance of these news reports, and that the format of the news - online newspapers - does not meet the quality level. If you have a revision and better sources to offer, please do. Zefr (talk) 20:33, 15 May 2022 (UTC)]
- Please, Zefr, I'm completely unable to follow what you are saying. None of the liver toxicity reports are from AYUSH (why on earth would they report such results when they have been recommending it quite freely for three years and continue to do so?). In direct contradiction of your "no clinical data" claim, the Drugs.com article reports multiple studies under "clinical data" and as I quoted, makes specific claims about safety at odds with your edit.
- You seem to be preoccupied with that Flavonol debate to the extent that you are totally confused here. Would you be amenable to restoring my edit and reverting your there is no evidence that it is effective or safe until you have time to properly review the references? Hemantha (talk) 04:52, 16 May 2022 (UTC)
- Let's deal with the Drugs.com source first. Under Uses and pharmacology in several sections: Antineoplastic effects - "no clinical data"; Antidiabetic and hypolipidemic effects - "no clinical data"; Antioxidant effects - small, weak studies (not a quote, but obvious); CNS effects - small, weak studies. Re-examine the left pyramid of MEDASSESS - no clinical data and small, weak studies are flashing lights for no-to-low evidence quality. Concerning your edit using the news sources reporting on uses and possible relationship to liver injury during Covid, we have only news summaries of a case report publication (low quality of evidence, MEDASSESS). Below is a draft to consider, although in my opinion, the evidence is too weak for the article. Zefr (talk) 15:42, 16 May 2022 (UTC)
- During the 2020-22
- Let's deal with the Drugs.com source first. Under Uses and pharmacology in several sections: Antineoplastic effects - "no clinical data"; Antidiabetic and hypolipidemic effects - "no clinical data"; Antioxidant effects - small, weak studies (not a quote, but obvious); CNS effects - small, weak studies. Re-examine the left pyramid of MEDASSESS - no clinical data and small, weak studies are flashing lights for no-to-low evidence quality. Concerning your edit using the news sources reporting on uses and possible relationship to liver injury during Covid, we have only news summaries of a case report publication (low quality of evidence, MEDASSESS). Below is a draft to consider, although in my opinion, the evidence is too weak for the article. Zefr (talk) 15:42, 16 May 2022 (UTC)
- Under Uses and pharmacology in the Drugs.com article, all the studies reviewed and discussion are about "no clinical data" concerning efficacy and safety. Concerning your sources - which are brief news reports,
References
- ^ a b Banjot Kaur (17 February 2022). "As COVID Surged, India Had a Silent Outbreak of Giloy-Induced Liver Injury". Science: The Wire.
- PMID 34230786.
Regarding addition of the content
@Velella- Regarding that controversial content in this article(Tinospora Cardifolia), there is no good evidence that it gives illness, rather some cases and that too is not a proper verification.[1]. Moreover, the statement itself don't have enough weightage to be published here. Regarding, Ministry of Ayush, I think the statements should be concluded there since Wikipedia is open sources and it's should tell both way. Please, I request to look carefully onto this. Edit:-I found some other Scientific papers like [1], this could be useful for this article. — Preceding unsigned comment added by 106.206.207.224 (talk) 14:38, 19 March 2023 (UTC)